JADE BIOSCIENCES INC
JBIONASDAQTrading Snapshot
- Day Range
- $14.05 – $14.25
- 52-Week Range
- $8.16 – $28.00
- Volume
- $3.22B
- Avg Volume
- $2.23B
- Shares Outstanding
- 60.9M
- Next Earnings
- Dec 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $149M
- Last Q Revenue
- $34M
- P/E Ratio
- -5.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.51
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +5855.0%
Why Investors Own JBIO
- ✓High-growth profile — revenue up +27.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 73% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
JADE BIOSCIENCES INC
JBIO
StockOtter · stockotter.spaceAbout JADE BIOSCIENCES INC
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Has Average Target Price of $51.75 According to Brokerages
Jade Biosciences, Inc. (NASDAQ: JBIO - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the firm, MarketBeat reports. One equities researc
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Jade Biosciences to Participate in Upcoming Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-clas
Jade Biosciences: Duration Is The Real Product
Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence versus competitors' more frequent regimens. Phase 1 data show JADE101 achieves ~70% IgA re
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical trial in IgA nephropat